Medication info
Daewoong Pioglitazone Metformin Tablets 15/850 mg

Daewoong Pioglitazone Metformin Tablets 15/850 mg

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Active

MFDS item code 201902248 · Approved 2019.04.12 · Insurance code 694003870

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily, and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to evaluate the safety and efficacy of switching to this medicine from other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be closely monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term blood glucose control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In the clinical use of this medicine, if blood glucose control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to evaluate changes in HbA1C.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar in patients with type 2 diabetes. It is particularly effective for patients who are also following a dietary regimen and exercise, as it contains both pioglitazone and metformin. This assists in maintaining blood sugar levels more steadily. Regular administration helps improve blood sugar control.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily, and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at the doses of pioglitazone and metformin they were previously receiving. No studies have been conducted to evaluate the safety and efficacy of switching to this medicine from other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not have their dose increased to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be closely monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to evaluate the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term blood glucose control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In the clinical use of this medicine, if blood glucose control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to evaluate changes in HbA1C.

Precautions

This medication contains two main ingredients, each contributing to blood sugar control. The first ingredient is metformin, and there is a risk of decreased kidney function or acute kidney injury during treatment, requiring regular kidney function tests. Metformin can rarely cause a serious metabolic condition known as lactic acidosis, which may present with symptoms such as muscle pain, fatigue, and difficulty breathing; if these symptoms occur, medical personnel should be notified immediately. Additionally, it is advisable that patients with impaired liver function or those who consume alcohol excessively avoid this medication. The second ingredient is pioglitazone, which may worsen heart failure, so care should be taken when administered to patients with heart disease or heart failure symptoms. This medication should not be used in patients with severe heart failure, and swelling due to fluid retention may occur; if symptoms develop, consultation with medical personnel is necessary. This medication is not recommended for patients with a history of bladder cancer or active bladder cancer. Symptoms such as urinary disturbances or hematuria should be reported to a physician immediately. Women who are pregnant or breastfeeding should not take this medication, and safety and efficacy have not been established in pediatric patients. In elderly patients, kidney function may be diminished, requiring careful adjustment of the initial dose and regular kidney function testing. During treatment, there may be interactions with other medications, so patients should inform medical personnel about all medications they are taking, especially those that may affect kidney or liver function. Before undergoing surgery or procedures involving iodine contrast agents, medication should be temporarily discontinued, and should be resumed once kidney function has been confirmed to be normal. Finally, patients taking this medication should regularly monitor their blood sugar and HbA1c levels to assess treatment effects, and due to the risk of vitamin B12 deficiency, it is advisable to check this through blood tests.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • lethargy
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 32 more
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • nausea
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • reduced vision
  • liver failure
  • congestive heart failure
  • edema
  • fracture
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intestinal gas retention
  • increased serum creatinine
  • increased blood urea
  • abnormal blood glucose
  • arthralgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain storage temperatures between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.